Key Highlights
- Maha Radhakrishnan, M.D. joins Sofinnova Investments as Executive Partner.
- Over 20 years of industry experience in drug development and commercialization.
- Former Chief Medical Officer of Biogen and senior VP at Sanofi.
- Expertise in guiding portfolio companies from clinical development to commercialization.
Source: Business Wire
Notable Quotes
- “Intentional and strategic growth of our team is core to our success, I believe Maha will be an exceptional asset to the Sofinnova team and portfolio as she brings decades of drug development expertise.” — Jim Healy, M.D., Ph.D., Managing Partner at Sofinnova Investments
- “I am thrilled to join the Sofinnova Investments team. This is a team with an incredible track record of focusing on robust science and high unmet medical needs.” — Maha Radhakrishnan, M.D., new Executive Partner at Sofinnova Investments
SoHC's Take
Sofinnova Investments’ strategic addition of Dr. Maha Radhakrishnan as an Executive Partner highlights the firm’s commitment to reinforcing its leadership with seasoned professionals. Dr. Radhakrishnan’s extensive background, including her roles as Chief Medical Officer at Biogen and senior VP at Sanofi, equips her with unparalleled expertise in drug development and commercialization. Her presence is expected to significantly bolster Sofinnova’s capacity to guide their portfolio companies through the complexities of clinical trials and market introduction. This move is anticipated to enhance Sofinnova’s robust portfolio and drive the development of innovative therapies, ultimately benefiting patients and the broader biopharmaceutical landscape.
